Myoglobin variants are expressed in human glioblastoma cells‑hypoxia effect? 2020

Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
Center for Aging and Associated Diseases, Helmy Institute for Medical Sciences, Zewail City of Science and Technology, Giza 12578, Egypt.

Glioblastoma multiforme (GBM) is the most aggressive human brain cancer. Little is known regarding how these cells adapt to the harsh tumor microenvironment, and consequently survive and resist various treatments. Myoglobin (MB), the oxygen‑binding hemoprotein, has been shown to be ectopically expressed in different human cancers and cell lines, and its expression is hypothesized to be an adaptation mechanism to hypoxia. The aim of the present study was to determine whether cancer‑related and hypoxia‑responsive MB mRNA splice variants are expressed in human GBM cells and glioblastoma tumor xenografts, and whether their expression is induced by hypoxia and correlated with hypoxia markers [lactate dehydrogenase A (LDHA), glucose transporter 1 (GLUT1), vascular endothelial growth factor (VEGF) and carbonic anhydrase IX (CAIX)]. Conventional reverse transcription (RT)‑PCR, DNA sequencing, RT‑quantitative PCR and immunohistochemistry were conducted to investigate MB expression in hypoxia‑sensitive (M010b, M059J) and ‑tolerant (M059K, M006xLo) GBM cell lines that also exhibit differential response towards radiation, rendering them a valuable translational GBM model. It was revealed that cancer‑related MB variants 9, 10, 11 and 13 were expressed in GBM cells under normoxia, and following hypoxia, their expression exhibited modest‑to‑significant upregulation that correlated with hypoxia markers. It was also demonstrated that MB was upregulated in hypoxic microregions of glioblastoma tumor xenografts that were stained in matched tumor regions of serial tumor sections with the hypoxia markers, pimonidazole, CAIX, VEGF and LDHA. The present study identified myoglobin as a potential contributor to the hypoxia adaptation and survival strategies of glioblastoma, and may explain the aggressiveness and frequent recurrence rates associated with GBM.

UI MeSH Term Description Entries
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D009211 Myoglobin A conjugated protein which is the oxygen-transporting pigment of muscle. It is made up of one globin polypeptide chain and one heme group.
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071231 Carbonic Anhydrase IX A carbonic anhydrase and transmembrane protein that consists of an N-terminal PROTEOGLYCAN-like domain, a catalytic region, a single-pass transmembrane domain, and a short intracellular tail. It functions as a dimer and is expressed primarily by cells of the GASTROINTESTINAL TRACT; BILE DUCT EPITHELIUM; and GALL BLADDER. It is expressed at high levels in many solid tumors, especially CLEAR CELL RENAL CARCINOMA, in response to CELL HYPOXIA. CAIX Protein,Carbonic Anhydrase 9
D000072258 Tumor Hypoxia Hypoxic conditions in tumor cells due to the tumor outgrowing its blood supply. It is associated with increased METASTASIS and resistance to RADIOTHERAPY and DRUG THERAPY. Tumor Cell Hypoxia,Cell Hypoxia, Tumor,Cell Hypoxias, Tumor,Hypoxia, Tumor,Hypoxia, Tumor Cell,Hypoxias, Tumor,Hypoxias, Tumor Cell,Tumor Cell Hypoxias,Tumor Hypoxias
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
February 2014, International journal of oncology,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
December 2008, Stem cells (Dayton, Ohio),
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
January 2018, Anti-cancer agents in medicinal chemistry,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
January 1992, Functional neurology,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
April 2014, Oncology reports,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
November 2000, Journal of neurochemistry,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
October 1970, The Biochemical journal,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
July 2004, Cancer research,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
August 2007, Neurochemical research,
Rana El-Tohamy, and Islam Elkholi, and Marwa E Elsherbiny, and Mona Magdy, and Olfat Hammam, and Joan Allalunis-Turner, and Marwan Emara
December 2011, BMC cancer,
Copied contents to your clipboard!